Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
2021-001661-21Phase 4Terminated
- Sponsor
- Herlev & Gentofte Hospital
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin, empagliflozin, semaglutide, telmisartan, losartan and 5 more in diabetic glomerulosclerosis, sponsored by Herlev & Gentofte Hospital. Started May 2021; status: terminated.
02
Drugs
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2021-001661-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001661-21.